Latest KFF Health News Stories
The NIH Ices a Research Project. Is It Self-Censorship?
The National Institutes of Health appeared to be digging into health misinformation. But then the federal agency stepped back. It can’t quite explain why, sometimes even offering contradictory explanations.
What the Health? From KFF Health News: Congress Is Out. The Presidential Campaign Is In.
Congress is in recess until after Labor Day, and lawmakers won’t have much time when they return to get the government funded before the next fiscal year. Meanwhile, the Republican campaign for president has begun in earnest, and while repealing the Affordable Care Act is no longer the top promise, some candidates have lively ideas about what to do with federal health programs. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Lauren Weber of The Washington Post join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Phil Galewitz, who reported the latest KFF Health News-NPR “Bill of the Month,” about how a bill that should never have been sent created headaches for one patient.
What the Health? From KFF Health News: Let’s Talk About the Weather
It’s been the summer of broken weather records around the world — for heat, rain, and wildfire smoke — advertising the risks of climate change in a big way. But, apparently, it’s not enough to break the logjam in Washington over how to address the growing climate crisis. Meanwhile, in Texas, women who were unable to get care for pregnancy complications took their stories to court, and Congress gears up to — maybe — do something about prescription drug prices. Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Rachel Cohrs of Stat join Julie Rovner, KFF Health News’ chief Washington correspondent, to discuss these issues and more. Also this week, Rovner interviews Meena Seshamani, the top administrator for the federal Medicare program.
Watch: Going Beyond the Script of ‘The G Word’ and How Government Responds to Disease (Or Not)
KHN Editor-in-Chief Elisabeth Rosenthal joins comedian Adam Conover to discuss his new Netflix series, “The G Word,” which examines the federal government’s role in Americans’ lives, and how it plays out in the covid era.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN’s ‘What the Health?’: Funding for the Next Pandemic
In his proposed budget, President Joe Biden called for a boost in health spending that includes billions of dollars to prepare for a future pandemic. But that doesn’t include money he says is needed immediately for testing and treating covid-19. Also this week, federal regulators authorized a second booster shot for people 50 and older yet gave little guidance to consumers about who needs the shot and when. Amy Goldstein of The Washington Post, Jennifer Haberkorn of the Los Angeles Times, and Rachana Pradhan of KHN join KHN’s Mary Agnes Carey to discuss these issues and more. Plus, Julie Rovner interviews KHN’s Julie Appleby, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a very expensive air ambulance ride.
KHN’s ‘What the Health?’: Congress Shelves Covid Funding for Now
The Biden administration’s request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate “synthetic” nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Fueron excluidas de los ensayos clínicos, una decisión que expertos cuestionan. Las dudas sobre si recomendar la vacuna contra COVID a las embarazadas al parecer ha generado más enfermedad y muerte.
Why Pregnant People Were Left Behind While Vaccines Moved at ‘Warp Speed’ to Help the Masses
Clinical trials of covid-19 vaccines excluded pregnant people, which left many women wondering whether to get vaccinated.
Wartime Trauma Hits Close to Home for Scholar of Dementia
The federal government is putting up $7.2 million for a study into the correlation between war trauma and dementia in Vietnamese immigrants. Oahn Meyer, an associate professor at the University of California-Davis who is leading the study, wonders whether her mother’s dementia is linked to trauma she suffered during the Vietnam War.
KHN’s ‘What the Health?’: Abortion Politics Front and Center
The polarizing abortion issue threatens to tie up Congress, the Supreme Court and the states for the coming year. Meanwhile, Congress kicks the can down the road to December on settling its spending priorities. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Yasmeen Abutaleb of The Washington Post and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
Also this week, Rovner interviews KHN’s Aneri Pattani, who delivered the latest KHN-NPR “Bill of the Month” episode about a covid test that cost as much as a luxury car.
Collins’ Skillful Piloting Helped NIH Steer Clear of Political Minefields
Dr. Francis Collins, who announced he is stepping down as chief of the National Institutes of Health, used his communication skills and political insights to help protect the highly acclaimed federal research institutes through difficult times.
Who Qualifies for a Covid Booster? The List Is Growing Longer
KHN’s Sarah Jane Tribble and Arthur Allen join Science Friday host Ira Flatow to recap the evolving news in the run-up to offering booster shots for the covid vaccine.
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.
Microbiome Startups Promise to Improve Your Gut Health, but Is the Science Solid?
A raft of startups are charging consumers hundreds of dollars to analyze the microbes in their gut and offer dietary advice based on the results. But scientists say scant research has been done, and as customers of one company have learned the hard way, the experience isn’t always smooth.
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
Fauci Thanks US Health Workers for Sacrifices but Admits PPE Shortages Drove Up Death Toll
Exclusive: The head of the National Institute of Allergy and Infectious Diseases says health workers ‘have lived up to the oath they take’ but says shortages of protective gear have contributed to excess deaths.
Medicamentos ya conocidos, y baratos, podrían ser clave para tratar covid
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
How Much of Trump’s Health Agenda Has Biden Undone?
In his campaign, President Joe Biden promised to undo policies, particularly health policies, implemented by former President Donald Trump. Yet, despite immense executive power, reversing four years of action takes time and resources.
